Erlotinib: early clinical development in brain cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erlotinib: early clinical development in brain cancer

Published:2014-05-16 Issue:7 Volume:23 Page:1027-1037
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Addeo Raffaele¹,Zappavigna Silvia²,Parlato Ciro³,Caraglia Michele²

Affiliation:

1. ASL NA2 NORD, Oncology Unit, Frattamaggiore, Italy

2. Second University of Naples, Department of Biochemistry, Biophysics and General Pathology, Via L. De Crecchio 7, 80138 Naples, Italy ; ;

3. Second University of Naples, Department of Neurosurgery, Viale Colli Aminei 21, Naples, Italy

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2014.918950

Reference89 articles.

1. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

2. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

3. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

4. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

5. Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics;Life Sciences;2024-05

2. Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A Review;Current Medicinal Chemistry;2024-01-30

3. Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma;Cancer Communications;2023-11-02

4. A scientometric analysis and up-to-date review of nano-based drug delivery systems in glioblastoma treatment;Nano Today;2023-10

5. A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study;Life;2023-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3